IL37 and Myocardial fibrosis: We showed in the present study that treatment with recombinant human IL‐37 significantly ameliorated ventricular remodeling after MI, as demonstrated by smaller infarct size, better cardiac function, lower mortality, restricted inflammatory responses, decreased myocardial fibrosis, and inhibited cardiomyocyte apoptosis.